Trial · NCT03938545
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Proptosis Response at Week 13 | RVT-1401 680 mg/Week | 30.0 | Percentage of participants | ||
| Percentage of Participants With Proptosis Response at Week 13 | RVT-1401 340 mg/Week | 30.8 | Percentage of participants | ||
| Percentage of Participants With Proptosis Response at Week 13 | RVT-1401 255 mg/Week | 0 | Percentage of participants | ||
| Percentage of Participants With Proptosis Response at Week 13 | Placebo | 8.3 | Percentage of participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs) | RVT-1401 680 mg/Week | TEAEs | 16 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs) | RVT-1401 340 mg/Week | TEAEs | 16 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs) | RVT-1401 255 mg/Week | TEAEs | 8 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs) | Placebo | TEAEs | 16 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs) | RVT-1401 680 mg/Week | SAEs | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs) | RVT-1401 340 mg/Week | SAEs | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs) | RVT-1401 255 mg/Week | SAEs | 1 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs) | Placebo | SAEs | 0 | Participants | |
| Least Square Mean Percent Change From Baseline in Binding Anti-thyroid-stimulating Hormone Receptor (TSHR) Antibody Levels to Week 13 | RVT-1401 680 mg/Week | -64.605 | 95% Confidence Interval -87.006 to -42.205 | Percent change | |
| Least Square Mean Percent Change From Baseline in Binding Anti-thyroid-stimulating Hormone Receptor (TSHR) Antibody Levels to Week 13 | RVT-1401 340 mg/Week | -69.663 | 95% Confidence Interval -89.272 to -50.054 | Percent change | |
| Least Square Mean Percent Change From Baseline in Binding Anti-thyroid-stimulating Hormone Receptor (TSHR) Antibody Levels to Week 13 | RVT-1401 255 mg/Week | -41.843 | 95% Confidence Interval -70.070 to -13.616 | Percent change | |
| Least Square Mean Percent Change From Baseline in Binding Anti-thyroid-stimulating Hormone Receptor (TSHR) Antibody Levels to Week 13 | Placebo | -4.520 | 95% Confidence Interval -25.580 to 16.539 | Percent change | |
| Least Square Mean Percent Change From Baseline in Total IgG Levels | RVT-1401 680 mg/Week | -79.101 | 95% Confidence Interval -86.444 to -71.757 | Percent change | |
| Least Square Mean Percent Change From Baseline in Total IgG Levels | RVT-1401 340 mg/Week | -65.103 | 95% Confidence Interval -71.687 to -58.519 | Percent change | |
| Least Square Mean Percent Change From Baseline in Total IgG Levels | RVT-1401 255 mg/Week | -57.934 | 95% Confidence Interval -67.216 to -48.651 | Percent change | |
| Least Square Mean Percent Change From Baseline in Total IgG Levels | Placebo | -6.098 | 95% Confidence Interval -12.948 to 0.753 | Percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03938545/results